EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer



Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer



International Journal of Clinical Oncology 14(1): 48-52



Recently, a high rate of brain metastases has been reported among patients with human epidermal growth factor receptor (HER2)-overexpressing metastatic breast cancer who were treated with trastuzumab. The present study examined risk factors for the development of brain metastasis in patients with HER2-overexpressing breast cancer who were treated with trastuzumab. We retrospectively reviewed 204 patients with HER-2-overexpressing breast cancer who were treated with a trastuzumab-containing regimen between 1999 and 2006. Patients with clinical symptoms were diagnosed as having brain metastases when brain magnetic resonance imaging (MRI) or a computed tomography (CT) scan revealed positive findings for brain metastases. The median follow-up time of this cohort was 53.6 months. Among the patients who received a trastuzumab-containing regimen, 74 patients (36.3%) developed brain metastases. The median survival from the diagnosis of brain metastases was 13.5 months (95% confidence interval [CI], 12.2-14.7 months). The median time interval between the beginning of trastuzumab treatment and the diagnosis of brain metastases was 13.6 months (range, 0.0-45.8 months). Among patients with brain metastases, the median overall survival period was 39 months. A multivariate logistic regression analysis showed that age (

(PDF emailed within 0-6 h: $19.90)

Accession: 051856772

Download citation: RISBibTeXText

PMID: 19225924

DOI: 10.1007/s10147-008-0797-8



Related references

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15(2): 219-225, 2005

Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. Journal of Clinical Oncology 23(16_suppl): 1568-1568, 2016

Clinical significance of brain metastases occurrence in HER2 overexpressing metastatic breast cancer patients treated with trastuzumab. Journal of Clinical Oncology 24(18_suppl): 10593-10593, 2016

Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer 22(5): 503-509, 2016

Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. Journal of Clinical Oncology 24(18_suppl): 1525-1525, 2016

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1130-1130, 2016

Predictive value of activated tyrosine kinase in patients with HER2-overexpressing metastatic breast cancer treated with trastuzumab + chemotherapy regimens. EJC Supplements 2(3): 173-174, March, 2004

Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy. Breast Cancer Research & Treatment 64(1): 123, November, 2000

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy. Journal of Clinical Oncology 26(15_suppl): 1053-1053, 2016

Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens. European Journal of Cancer Supplements 2(3): 173-174, 2004

Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 23(16_suppl): 803-803, 2016

Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy. 2007

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. Journal of Clinical Oncology 29(23): 3126-3132, 2011

Promising Novel Approaches for Metastatic HER2-Overexpressing Breast Cancer Progressing on Trastuzumab: (1) Pertuzumab+Trastuzumab Active after Failed Sequential Therapy; (2) Adding Lapatinib & Continuing Trastuzumab Better than Lapatinib Alone, Reinforcing Trastuzumab Use Beyond Progression; (3) Trastuzumab+Ridaforolimus Effective in Heavily Pretreated Patients; (4) T-DM1 Shrinks Tumors after Multiple Previous Treatments. Oncology Times 32(Sup 1): 2-6, 2010

Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer. Breast 14(5): 425-425, 2005